MétaCan
Menu
← Retour à la cohorte
Enregistrement W4417002206 · doi:10.1182/blood-2025-3547

Evaluating targeted long-read sequencing as a diagnostic tool for burkitt lymphoma

2025· article· en· W4417002206 sur OpenAlexaff
Giuliano Banco, Kostiantyn Dreval, Laura K. Hilton, David W. Scott, Michael J. Trimble, Amy Huei‐Yi Lee, Krysta M. Coyle, Ryan D. Morin

Notice bibliographique

RevueBlood · 2025
Typearticle
Langueen
DomaineBiochemistry, Genetics and Molecular Biology
ThématiqueCancer Genomics and Diagnostics
Établissements canadiensCanada's Michael Smith Genome Sciences CentreSpinal Cord Injury BCSimon Fraser University
Organismes subventionnairesnon disponible
Mots-clésGermlineDNA sequencingEpigeneticsLymphomaSomatic cellDNA methylationGermline mutationMutationKRAS

Résumé

récupéré en direct d'OpenAlex

Abstract Introduction: While sporadic in developed countries, Burkitt lymphoma (BL) is endemic in resource-limited regions. Given the one-year survival rates of 61% (Mezger, The Oncologist, 2023), BL patients in sub-Saharan Africa could benefit from improved diagnostic methods, particularly those that facilitate the evaluation of new targeted agents. Recent work from our group has found that BL can now be divided into molecular subgroups based on mutations (Thomas, Blood, 2023) and into epitypes using DNA methylation patterns (Thomas, BCD, 2025). Nanopore long-read sequencing is becoming a robust and efficient approach to rapidly profile patient DNA samples for structural variants (SVs), simple somatic mutations (SSMs) and base modifications. Using the adaptive sampling (AS) technique, sequencing can be focused on regions of interest (ROIs). This technique has shown promise in application to germline genetics (Vermuelen, Nature, 2023) but its potential application to somatic conditions remains largely unexplored. We are evaluating the utility of this approach to obtain genetic and epigenetic data from relevant genomic loci to facilitate differential diagnosis and accurate assignment of BL molecular subgroup and epitype. We aim to create a diagnostic assay using AS coupled with an automated bioinformatics pipeline that classifies and subtypes BL to inform treatment and improve outcomes in resource-limited regions. Methods: To establish ROIs, we selected driver mutations and features identified as relevant to differentiating BL from other B-cell lymphomas (Coyle, Blood Adv., 2025) as well as distinguishing epitype (Thomas, BCD, 2025) and molecular subgroup (Thomas, Blood, 2023). These include 179 lymphoma genes, 3 oncogenic SVs, 127 regions commonly affected by aberrant somatic hypermutation, the EBV genome, the IGH, IGK and IGL loci, collectively 31.5 megabases. Initially, we simulated AS data for 9 BL genomes by extracting reads corresponding to ROIs with samtools from whole genome sequencing data (PromethION). To generate real AS data, we prepared 32 µL of DNA library using the Raji BL cell line. Library preparation with 1.6 µg of gDNA was performed according to the Native Barcoding Kit 24 V14 (SQK-NBD114.24) protocol. The library was sequenced on a single PromethION flow cell (R10.4.1 chemistry) for 25 hours in enrichment mode using our ROI panel. Enrichment, coverage and relevant AS metrics were assessed using samtools, bedtools, Mosdepth, custom R scripts and MinKNOW output files. To evaluate epitype classification, CpG methylation status was inferred from simulated AS data with Modkit, analyzed with custom R scripts and compared to ground truth labels. To explore 5hmC modification and hypomethylation patterns, TET2 expression was determined from RNAseq data (n=126) and analyzed using R scripts. To examine mutation differences between epitypes, SLMS-3 (Thomas, Blood, 2023) variant calls within ROIs from Illumina data for the same 9 BL genomes were used; these were normalized and compared using custom R scripts. Results: The top 6,000 5mC positions with the highest variance were able to accurately recapitulate patient epitypes. These positions had an average CpG methylation level of 49% in HyperBL and 36% in HypoBL. HyperBL samples showed more mutations than HypoBL, consistent with the ground truth. TET2 expression was significantly greater in HypoBL, suggesting more demethylation and higher transient 5hmC modification during demethylation. Regarding AS metrics, 4.7% of fragments present were basecalled. A total of 1.7 million fragments were sequenced and 23.2% overlapped a target ROI. Mean read lengths for on and off-target fragments were 7,065 and 690 bases, respectively, and the range of quality scores for these reads was comparable. Average coverage across ROIs was 67.9, with an enrichment factor of 79.3. Conclusions: Preliminary analysis of real and simulated BL AS data suggests that a limited feature set can support successful subgroup classification concordant with Illumina ground truths. Evaluation of ONT-focused tools to resolve SSMs and SVs is ongoing. Our preliminary results suggest AS has the potential to serve as a portable, high-throughput diagnostic assay to inform treatment and improve outcomes for endemic BL patients in resource-limited regions.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,002
score de la tête « metaresearch » (Gemma)0,003
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Expérimental (laboratoire) · Signal consensuel: Expérimental (laboratoire)
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,002
Score d'incertitude au seuil0,011

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0020,003
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,000
Bibliométrie0,0010,000
Études des sciences et des technologies0,0000,000
Communication savante0,0010,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,000
Charge utile insuffisante (le modèle a refusé de juger)0,0010,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,016
Tête enseignante GPT0,301
Écart entre enseignants0,286 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeExpérimental (laboratoire)
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations1
Publié2025
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueBlood→Même sujetCancer Genomics and Diagnostics→Travaux en français237 207→